'On consolidated basis
Quarter ended December 2024 compared with Quarter ended December 2023.
Net sales (including other operating income) of Ipca Laboratories has increased 9.38% to Rs 2245.37 crore. Operating profit margin has jumped from 16.12% to 20.62%, leading to 39.95% rise in operating profit to Rs 463.08 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 29.29% to 21.46%. Purchase of finished goods cost rose from 5.59% to 8.38%. Employee cost decreased from 22.05% to 21.60%. Other expenses rose from 27.18% to 27.97%.
Other income fell 10.42% to Rs 20.11 crore. PBIDT rose 36.75% to Rs 483.19 crore. Provision for interest fell 49.67% to Rs 16.81 crore.
PBDT rose 45.78% to Rs 466.38 crore. Provision for depreciation fell 1.05% to Rs 98.46 crore.
Profit before tax grew 66.9...
Pleaselogin & subscribe to view the full report.
More Reports
|
|